Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$10.65
+2.6%
$9.36
$6.38
$17.30
$1.00B1.421.23 million shs1.64 million shs
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.18
$0.46
$17.51
$978.01M-0.1390,307 shs22,300 shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.65
$0.72
$6.24
$258.25M2.27944,487 shsN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$6.78
+1.2%
$6.29
$4.95
$12.83
$478.66M0.94714,963 shs221,368 shs
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$0.10
+4.2%
$0.07
$0.06
$0.61
$4.08M2.4694,981 shs33,969 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
+2.60%+11.52%+12.11%+32.63%-37.02%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00%0.00%0.00%0.00%0.00%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%0.00%+0.76%+335.02%-30.68%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
+1.19%-1.74%+4.31%+13.19%-26.94%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
+4.24%+38.51%+35.90%-15.16%-82.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
1.8485 of 5 stars
3.51.00.00.01.61.70.6
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.6532 of 5 stars
0.00.00.04.80.60.80.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.4875 of 5 stars
4.24.00.00.02.72.50.0
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.2235 of 5 stars
0.03.00.00.02.00.83.1
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.0416 of 5 stars
3.03.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$18.1770.58% Upside
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00
N/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00
N/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.00
Hold$1.751,637.84% Upside

Current Analyst Ratings Breakdown

Latest FIXX, SPRB, AVDL, INZY, and SIGA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M6.09N/AN/A$0.77 per share13.83
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.16M0.00N/AN/A$1.26 per share0.00
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$120.33M4.03$0.85 per share8.01$3.02 per share2.25
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$4.91M0.87N/AN/A$1.88 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.27N/A177.50N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$59.21M$0.6710.125.42N/A40.30%25.21%22.05%7/30/2025 (Estimated)
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$47.92M-$1.32N/AN/AN/A-555.23%-62.10%-47.49%8/11/2025 (Estimated)

Latest FIXX, SPRB, AVDL, INZY, and SIGA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$0.25N/AN/AN/A$0.67 millionN/A
8/5/2025Q2 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.36N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/8/2025Q1 2025
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A-$0.01N/A-$0.01N/A$7.04 million
5/7/2025Q1 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.73
2.33
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/A
7.25
7.25
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
8.40
6.28
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.01
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
31.32%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7096.74 million91.71 millionOptionable
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
758.13 million48.77 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.44 million70.05 millionOptionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2042.23 million37.54 millionOptionable

Recent News About These Companies

SPRB Spruce Biosciences, Inc. - Seeking Alpha
Spruce Biosciences Inc Ordinary Shares
Spruce Biosciences (SPRB) Receives a Hold from RBC Capital
Spruce Biosciences reports delayed annual filing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$10.65 +0.27 (+2.60%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$10.64 -0.01 (-0.05%)
As of 07/16/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Homology Medicines stock logo

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$6.78 +0.08 (+1.19%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$6.80 +0.02 (+0.29%)
As of 07/16/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Spruce Biosciences stock logo

Spruce Biosciences NASDAQ:SPRB

$0.10 +0.00 (+4.24%)
As of 07/16/2025 03:32 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.